Fight Cancer Now $BMY
Today, Bristol announced that Opdivo (PD-1)/ Yervoy (CTLA-4) in CM- 214 study for 1L mRCC (kidney cancer) was stopped early after meeting its OS endpoint, ahead of Street’s expectations. I think this bodes well for the pivotal small cell lung cancer trial underway.